60 Years of Scientific Excellence

When the Cancer Research Institute was founded in 1953, we knew then that immune-based treatments would transform cancer medicine. In more than six decades since, we've made numerous groundbreaking discoveries that have given more patients new hope today.

Partnerships

The Anna-Maria Kellen Clinical Accelerator is jointly managed by the Cancer Research Institute and Ludwig Cancer Research, two leading cancer research nonprofit organizations committed to driving innovation in the field of immuno-oncology.

Cancer Research Institute

Public nonprofit organization established in 1953 dedicated exclusively to advancing research in cancer immunology and development of cancer immunotherapies

~$30 million in research grants per year with over $280 million invested since inception

In 2010, established a nonprofit venture capital fund to make investments in priority clinical trials in partnership with leading biopharma companies

Ludwig Cancer Research

International nonprofit foundation established in 1971 committed to integrated laboratory and clinical discovery to improve the understanding and control of cancer

>40 ongoing product development programs based on IP or technologies from Ludwig

Biotech and Pharmaceutical Company Partnerships

Cancer Research Institute and Ludwig Cancer Research partner with leading biopharma companies to access priority drugs for inclusion in our clinical studies. These partners represent the best of what’s new in the field of immuno-oncology, and through our work with them, our network of researchers are able to access more than 30 of the most promising new treatments for clinical study.

CVAC

CRI, Ludwig, and CureVac, announced that they will collaborate to enable clinical testing of novel cancer immunotherapy treatments.

The non-profit Cancer Research Institute (CRI) and Ludwig Cancer Research (Ludwig), and CureVac, a clinical stage biopharmaceutical company that has pioneered the development of a new class of therapies and vaccines based on messenger RNA (mRNA), today announced that they will collaborate to enable clinical testing of novel cancer immunotherapy treatment options. - See more at: http://cancerresearch.org/news/2013/november/curevac-collaborates-with-cancer-research-institute-and-ludwig-to-enable-clinical-testing-of-cancer-immunotherapies#sthash.UBPibWEn.dpuf

The non-profit Cancer Research Institute (CRI) and Ludwig Cancer Research (Ludwig), and CureVac, a clinical stage biopharmaceutical company that has pioneered the development of a new class of therapies and vaccines based on messenger RNA (mRNA), today announced that they will collaborate to enable clinical testing of novel cancer immunotherapy treatment options. - See more at: http://cancerresearch.org/news/2013/november/curevac-collaborates-with-cancer-research-institute-and-ludwig-to-enable-clinical-testing-of-cancer-immunotherapies#sthash.UBPibWEn.dpuf

The non-profit Cancer Research Institute (CRI) and Ludwig Cancer Research (Ludwig), and CureVac, a clinical stage biopharmaceutical company that has pioneered the development of a new class of therapies and vaccines based on messenger RNA (mRNA), today announced that they will collaborate to enable clinical testing of novel cancer immunotherapy treatment options. - See more at: http://cancerresearch.org/news/2013/november/curevac-collaborates-with-cancer-research-institute-and-ludwig-to-enable-clinical-testing-of-cancer-immunotherapies#sthash.UBPibWEn.dpuf

CRI and Ludwig will focus on VentiRx's motolimod (VTX-2337), a Toll-like receptor 8 agonist, for clinical testing of novel combinations.

Other Nonprofit Partnerships

Because immunotherapy is a platform technology with application to myriad types of cancer, CRI seeks out partnerships with leading indication-specific cancer nonprofits. Through these invaluable partnerships, CRI is able to tap into leading scientific experts for specific types of cancer and secure valuable co-funding for its network’s most promising immunotherapy clinical trial ideas for a particular type of cancer.